Biotechnology Technology Transfer Law In Ukraine.
1. Introduction
Biotechnology technology transfer law in Ukraine governs the legal transfer, licensing, commercialisation, development and international exchange of biotechnology-related knowledge, inventions, scientific discoveries and industrial processes.
Technology transfer is particularly important in biotechnology because scientific research often produces commercially valuable innovations, including:
Genetic engineering and gene-editing technologies.
Recombinant DNA and protein technologies.
Vaccine and pharmaceutical manufacturing processes.
Stem-cell and tissue-engineering technologies.
Genetically modified organisms (GMOs).
Agricultural and industrial biotechnology.
Synthetic biology and microbial technologies.
Biopharmaceutical research and development.
Diagnostic technologies and biological testing systems.
Ukraine regulates technology transfer through intellectual property legislation, contractual law, biotechnology and biosafety legislation, innovation policies and international trade obligations.
The principal legislation is the Law of Ukraine No. 143-V of 14 September 2006, On State Regulation of Activities in the Field of Technology Transfer.
This legislation establishes the legal, economic, organisational and financial framework for transferring technologies and protecting associated property rights. Its consolidated version includes amendments through 12 December 2025.
on September 14, 2006 № 143-V+1
An important distinction is that Ukraine does not have one comprehensive statute dealing exclusively with biotechnology technology transfer. Instead, several laws operate together.
2. Constitutional and Legal Foundations
The Ukrainian legal framework recognises intellectual property, scientific development, economic activity and technological innovation as important legal interests.
The principal legal foundations include:
Constitution of Ukraine – protection of property and intellectual property rights.
Civil Code of Ukraine – contractual arrangements and intellectual property ownership.
Law No. 143-V of 2006 – technology transfer.
Law on the Protection of Rights to Inventions and Utility Models – patent protection.
Law on Scientific and Scientific-Technical Activity – research and scientific development.
Law on Innovation Activity – innovation and commercialisation.
Law No. 3339-IX of 2023 – regulation of genetic engineering and GMOs.
Legislation on international transfers of military and dual-use goods.
These laws collectively regulate the transfer of biotechnology from universities, research institutions and private laboratories to commercial manufacturers and international partners.
3. Law on State Regulation of Activities in the Field of Technology Transfer, 2006
Principal legislation
Law No. 143-V is the central legal instrument governing technology transfer in Ukraine.
It covers the transfer of technologies and their constituent elements through written agreements between individuals and legal entities.
Its definition of technology encompasses scientific knowledge, technical solutions, organisational arrangements and processes used in manufacturing products or providing services.
For biotechnology, this can include:
Laboratory protocols.
Genetic engineering techniques.
Microorganism production methods.
Pharmaceutical manufacturing procedures.
Biological research documentation.
Patent rights and technical know-how.
Specialised biotechnology equipment.
The law also recognises dual-use technologies, meaning technologies that have civilian applications but could potentially be used for military or special purposes.
Legal significance: A biotechnology transfer is not limited to selling a patent. It can involve the transfer of technical documentation, manufacturing knowledge, intellectual property rights, equipment-related expertise and contractual permissions.
on September 14, 2006 № 143-V+1
4. Ownership of Biotechnology Developed Through Public Funding
Ownership is one of the most important issues in Ukrainian biotechnology technology transfer.
Article 11 of Law No. 143-V addresses technologies developed through publicly funded research and development.
Generally, proprietary rights in technologies developed using state-budget funds belong to the institutions, organisations or enterprises that perform the research.
However, exceptions apply, including circumstances involving state secrets and other legally prescribed cases.
Where technology is developed through a combination of public funding and the institution's or private parties' own resources, ownership should be determined in accordance with the applicable legislation and the relevant agreements.
Example:
A Ukrainian public university develops a genetically engineered microorganism using government research funding.
A pharmaceutical company subsequently wishes to manufacture a commercial product using that microorganism.
The parties must establish:
Who owns the microorganism-related invention.
Whether the university owns the relevant patent rights.
Whether researchers retain authorship rights.
Whether the government has any applicable rights.
Whether the company requires a licence or assignment.
How royalties and commercial profits will be distributed.
A company cannot assume that funding research automatically gives it ownership of every resulting invention.
CIS Legislation+1
5. Patent Protection in Biotechnology Technology Transfer
Patent protection is fundamental to transferring biotechnology inventions.
Ukraine's Law on the Protection of Rights to Inventions and Utility Models establishes the framework for patent ownership, licensing and assignment.
Potentially patentable biotechnology inventions include:
New biological manufacturing processes.
Recombinant proteins.
Certain genetically engineered microorganisms.
Novel pharmaceutical compositions.
Biotechnological production methods.
Certain diagnostic and laboratory technologies.
Patentability depends on statutory requirements, including novelty, inventive step and industrial applicability, together with applicable exclusions.
A patent holder may transfer proprietary rights through an agreement or authorise another person to use the invention through a licence agreement.
The relevant agreement must satisfy the applicable written-form requirements.
WIPO Lex+1
Example:
A Ukrainian research institute develops a patented method for manufacturing a recombinant therapeutic protein.
It may:
Assign the patent to a pharmaceutical company.
Grant an exclusive licence.
Grant a non-exclusive licence.
Negotiate territorial licensing rights.
Enter into a research and manufacturing collaboration.
The agreement should distinguish ownership of the invention from permission to manufacture and commercialise products.
6. Technology Transfer Agreements
Technology transfer agreements are central to the commercialisation of biotechnology in Ukraine.
Article 19 of Law No. 143-V identifies important contractual conditions.
These include:
Identification of the technology and its constituent elements.
Functional characteristics and guaranteed performance indicators.
Technology price or payment for its use.
Time, place and method of transfer.
Transfer of technical knowledge and documentation.
Licence conditions.
Territorial limitations.
Restrictions on the field of application.
For biotechnology agreements, additional provisions are particularly important.
| Contractual provision | Biotechnology significance |
|---|---|
| Patent ownership | Identifies the legal owner |
| Know-how transfer | Protects confidential laboratory knowledge |
| Biosafety obligations | Regulates safe handling |
| Quality standards | Ensures manufacturing consistency |
| Research materials | Identifies transferred biological materials |
| Royalty provisions | Determines financial compensation |
| Confidentiality | Protects research information |
| Liability clauses | Allocates responsibility for damage |
| Termination | Regulates the end of transfer rights |
A well-drafted agreement should also address improvements, derivative inventions, research publications, access to biological samples, regulatory approvals and post-termination obligations.
zakon.rada.gov.ua+1
7. Licensing of Biotechnology Technologies
Licensing permits another organisation to use biotechnology without necessarily transferring ownership.
The Civil Code of Ukraine, particularly Articles 1107–1113, provides the general framework for intellectual property disposal agreements. Article 1109 addresses licensing agreements.
Common licensing arrangements include:
A. Exclusive licensing
The licensee receives exclusive rights within the agreed contractual scope. The agreement should clearly identify whether the licensor retains any rights to use the technology.
B. Non-exclusive licensing
The owner may authorise multiple companies or research institutions to use the same technology.
C. Territorial licensing
A biotechnology company may receive rights to manufacture products in Ukraine, while another company receives rights for the European Union.
D. Research licensing
A university may permit another institution to use patented technology for specified research purposes.
E. Manufacturing licensing
A pharmaceutical manufacturer receives permission to use biological production methods under specified quality and regulatory conditions.
The parties should expressly define sublicensing, royalties, technical assistance, regulatory responsibilities and infringement enforcement.
wwwex.ilo.org+1
8. Know-How and Trade Secret Protection
Biotechnology technology transfer frequently involves information that cannot be adequately protected through patents alone.
Examples include:
Fermentation techniques.
Cell-culture conditions.
Protein purification processes.
Laboratory protocols.
Proprietary genetic sequences and methods.
Production parameters.
Quality-control procedures.
Under Ukrainian law, commercially valuable confidential information may qualify for protection as a commercial secret if it is secret, has commercial value because of its secrecy and is subject to appropriate measures to maintain confidentiality.
Technology transfer agreements should therefore contain:
Non-disclosure obligations.
Restrictions on unauthorised use.
Controlled access to laboratory information.
Employee confidentiality requirements.
Restrictions on disclosure to third parties.
Return or destruction of confidential materials.
Procedures for investigating information leaks.
Example: A Ukrainian biotechnology company transfers a patented vaccine-production process to a foreign manufacturer but retains confidential information concerning purification and stabilisation techniques.
The patent licence alone may not adequately protect this confidential knowledge. Separate know-how and confidentiality provisions are necessary.
9. Transfer of Genetically Modified Organisms and Biosafety Requirements
Important 2026 legislative development
Biotechnology transfer involving genetically modified organisms is subject to additional regulatory controls.
Ukraine adopted Law No. 3339-IX on 23 August 2023, concerning state regulation of genetic engineering activities and state control over the placing of genetically modified organisms and products on the market.
This legislation replaced the earlier GMO biosafety framework from 16 September 2026.
zakon.rada.gov.ua+2
The framework addresses:
Genetic engineering activities in contained systems.
Research and testing involving GMOs.
GMO registration.
Commercial circulation of GMOs.
Import and export.
Transportation and handling.
Environmental and biological safety.
For biotechnology technology transfer, this means that transferring a GMO-related patent or manufacturing protocol does not automatically authorise the recipient to conduct every associated genetic engineering activity.
Separate regulatory permissions and compliance obligations may apply.
Example:
A Ukrainian biotechnology research centre transfers a genetically modified microorganism to an overseas industrial biotechnology company.
The parties must examine:
Whether the microorganism is subject to registration.
Whether the proposed activity involves a contained or open system.
Whether import or export authorisation is required.
Whether risk assessment is necessary.
Whether transportation and storage requirements are satisfied.
Whether the intended commercial application is authorised.
The regulatory framework is particularly important for agricultural biotechnology, industrial microorganisms and environmental applications.
10. International Biotechnology Technology Transfer
Ukraine participates in international scientific and technological cooperation.
Cross-border biotechnology transfers can involve:
Foreign patent licensing.
Joint research agreements.
International vaccine manufacturing.
Pharmaceutical technology partnerships.
University-to-industry collaboration.
Export of biological manufacturing expertise.
Import of laboratory equipment and biological materials.
International transactions must comply with Ukrainian law and applicable international obligations.
Relevant legal frameworks include:
A. EU-Ukraine Association Agreement
The Agreement provides a framework for economic, scientific and technological cooperation and intellectual property protection.
B. WTO obligations
International trade rules may become relevant where biotechnology products, agricultural materials or technology-related goods are transferred across borders.
C. Cartagena Protocol on Biosafety
The Protocol is relevant to international movements of living modified organisms where its scope and applicable procedures are engaged.
D. Dual-use export controls
Biotechnology equipment, biological agents, technical information and related materials may fall within dual-use control rules depending on their characteristics, destination and intended use.
A company must therefore distinguish ordinary commercial biotechnology from transfers that require additional export-control review.
11. Export Controls and Dual-Use Biotechnology
Technology transfer can create national-security concerns where biotechnology has both civilian and military applications.
Examples include:
Certain pathogen-related research.
Specialised biological production equipment.
Genetic engineering technologies.
Certain laboratory containment systems.
Controlled biological materials.
Technical information concerning restricted biological processes.
Ukraine's Law on State Control over International Transfers of Military and Dual-Use Goods establishes a relevant control framework.
A biotechnology company should conduct an export-control assessment before transferring controlled technology, equipment or materials to an overseas recipient.
Important compliance considerations include:
Classification of the technology.
Identification of the recipient.
Assessment of the destination country.
Examination of the intended end use.
Verification of applicable licences and permissions.
Maintenance of transfer documentation.
An intellectual property licence does not override export-control requirements.
12. Technology Transfer from Universities and Research Institutions
Universities and public research institutions are important sources of biotechnology innovation in Ukraine.
Their activities may include:
Developing new biological medicines.
Creating genetically engineered microorganisms.
Conducting vaccine research.
Developing diagnostic technologies.
Researching stem-cell applications.
Producing agricultural biotechnology innovations.
Technology transfer may take place through university spin-offs, research partnerships, patent licensing and commercialisation agreements.
However, disputes can arise concerning ownership between researchers, universities, funding bodies and commercial partners.
A research institution should establish clear internal policies governing:
Invention disclosure.
Employee and researcher inventions.
Ownership of research results.
Funding conditions.
Patent application expenses.
Revenue sharing.
Commercialisation rights.
Law No. 143-V also provides for remuneration arrangements involving technology authors and persons involved in technology transfer.
Cabinet of Ministers Resolution No. 1030 of 4 December 2019 is relevant to minimum remuneration rates for technology authors and persons carrying out transfers.
WIPO Lex+1
13. Royalty Payments and Financial Responsibilities
Technology transfer frequently involves payments to inventors, research institutions and technology owners.
Possible financial arrangements include:
Initial licensing fees.
Annual licence payments.
Running royalties.
Milestone payments.
Manufacturing royalties.
Revenue-sharing arrangements.
Payments for technical assistance.
For example, a biotechnology university may license a patented microbial production technology to a pharmaceutical company.
The agreement might provide for an initial payment, milestone payments after successful validation and royalties based on commercial sales.
The contract should clarify how royalties are calculated, when payments become due, what records must be maintained and whether the licensor has audit rights.
The parties must also consider applicable Ukrainian taxation, foreign-exchange and international payment requirements.
14. Liability for Unlawful Biotechnology Technology Transfer
Unlawful biotechnology transfers may create civil, administrative or criminal liability, depending on the nature of the violation.
Potential violations include:
Unauthorised patent licensing.
Misappropriation of confidential laboratory information.
Breach of research agreements.
Unlawful transfer of biological materials.
Violation of GMO regulatory requirements.
Export-control violations.
Unauthorised commercial use of patented inventions.
Misrepresentation concerning technology ownership.
Available legal remedies may include:
Injunctions.
Compensation for damages.
Recovery of unpaid royalties.
Recognition of intellectual property rights.
Termination of unlawful use.
Contractual remedies.
Applicable administrative or criminal sanctions.
For a biotechnology business, contractual liability and regulatory liability must be considered separately.
A company may have a valid technology transfer agreement but still violate biosafety or export-control legislation through its actual activities.
15. Important Ukrainian Case Laws
There is an important qualification: publicly identifiable Ukrainian Supreme Court decisions directly concerning biotechnology technology-transfer agreements are limited. However, several intellectual property and pharmaceutical patent decisions establish principles that are highly relevant to biotechnology licensing, ownership and commercialisation.
Case 1. Supreme Court of Ukraine – Case No. 366/599/19
Directly relevant to technology-transfer contracts
Court: Civil Cassation Court of the Supreme Court.
Decision: 13 April 2022.
Subject: Transfer of rights to inventions.
Facts:
The parties entered into an agreement transferring rights relating to inventions for which patents had not yet been registered.
A dispute arose concerning the legal character of the agreement and whether statutory requirements applicable to licence agreements made the agreement invalid.
Legal issue:
Whether an agreement transferring rights to inventions should automatically be treated as a licence agreement.
Judgment:
The Supreme Court considered the agreement to be an innominate contract combining different forms of intellectual property rights disposal.
It held that the relevant Civil Code provisions concerning invalid licence-agreement terms did not automatically apply to this differently characterised contract.
Importance for biotechnology:
This decision is relevant to agreements transferring:
Genetic engineering inventions.
Pharmaceutical research results.
Biological manufacturing technologies.
Biotechnology patent applications.
Research and development rights.
It demonstrates that courts examine the actual substance of a technology-transfer agreement rather than merely its title.
court.gov.ua+1
Case 2. Supreme Court of Ukraine – Case No. 569/9366/17
Court: Civil Cassation Court of the Supreme Court.
Decision: 15 September 2021.
Subject: Disposal of proprietary intellectual property rights.
Legal issue:
Whether the statutory forms of agreements for disposing of intellectual property rights constitute an exhaustive list.
Judicial principle:
The Supreme Court recognised that Article 1107 of the Civil Code does not provide an exhaustive list of possible contractual arrangements concerning the disposal of proprietary intellectual property rights.
Importance for biotechnology:
Biotechnology companies may structure complex transactions combining:
Patent assignments.
Research collaboration.
Technical know-how.
Manufacturing rights.
Commercialisation arrangements.
The decision supports examining the actual contractual obligations rather than relying exclusively on a particular contract label.
court.gov.ua+1
Case 3. Supreme Court of Ukraine – Case No. 757/49581/23-ц
Court: Civil Cassation Court of the Supreme Court.
Decision: 13 March 2025.
Subject: Registration of intellectual property rights transfers.
Legal issue:
Whether the absence of state registration of a transfer of proprietary intellectual property rights makes the underlying written agreement invalid.
Judgment:
The Supreme Court explained the distinction between the validity of a written agreement and the legal effect of registration.
The absence of registration does not, by itself, invalidate the written agreement. However, until registration, the proprietary rights do not arise in the acquirer in the manner required for full protection of those transferred rights.
Importance for biotechnology:
This principle is important when transferring:
Pharmaceutical patents.
Genetic engineering inventions.
Biotechnology manufacturing patents.
Other registered intellectual property rights.
Companies should carefully complete the relevant registration procedures instead of relying solely on signed contracts.
court.gov.ua
Case 4. Supreme Court of Ukraine – Case No. 910/9215/21
Court: Commercial Cassation Court of the Supreme Court.
Subject: Caspofungin-Teva pharmaceutical patent dispute.
Decision: Reported in 2023.
Facts:
The dispute concerned a pharmaceutical product containing an active ingredient allegedly protected by another company's patent.
The patent owner challenged the regulatory registration activities associated with the competing pharmaceutical product.
Legal issue:
Whether acts undertaken in preparation for commercialising a pharmaceutical product could interfere with existing patent rights before actual commercial sales.
Importance:
The case illustrates the importance of patent protection during the pharmaceutical regulatory approval process.
For biotechnology companies, similar considerations arise when licensing or commercialising:
Biopharmaceutical products.
Recombinant proteins.
Biological medicines.
Vaccine technologies.
Patent-protected pharmaceutical compositions.
This is a pharmaceutical patent precedent, not a direct biotechnology technology-transfer judgment.
Law Gratis+1
Case 5. Supreme Court of Ukraine – Case No. 910/9528/25
Court: Commercial Cassation Court of the Supreme Court.
Decision: 30 April 2026.
Subject: Supplementary patent protection for a pharmaceutical invention.
Facts:
The dispute concerned a patent relating to the active pharmaceutical ingredient of the GARDASIL 9 vaccine.
The patent holder argued that the patent remained in force under wartime intellectual property legislation and that supplementary protection was available.
Judgment:
The Supreme Court dismissed the cassation appeal and upheld the conclusion that the patent remained protected under the applicable wartime legislation.
It also recognised the compensatory purpose of supplementary patent protection for pharmaceutical inventions.
Importance for biotechnology:
This decision is relevant to technology transfer involving vaccines and biological medicines because patent duration and supplementary protection can materially affect licensing value, investment and commercialisation strategies.
court.gov.ua
16. Relationship Between Biotechnology Technology Transfer and EU Law
Ukraine's technology-transfer framework is also influenced by its international cooperation and European integration commitments.
Important areas include:
| Legal area | Relevance |
|---|---|
| EU intellectual property standards | Patent and licensing protection |
| EU biotechnology regulation | GMO and biological safety |
| Pharmaceutical regulation | Medicine development and authorisation |
| Research cooperation | University and industry partnerships |
| Data protection | Genetic and clinical research information |
| Export controls | Restricted biological technologies |
| International trade | Cross-border biotechnology transactions |
The European Union framework is particularly important where Ukrainian biotechnology companies intend to transfer technologies to European pharmaceutical manufacturers.
However, compliance with Ukrainian technology-transfer law does not automatically establish compliance with all applicable EU regulatory requirements.
17. Major Legal Challenges
Ukraine faces several legal and practical challenges concerning biotechnology technology transfer.
A. Ownership disputes
Conflicts may arise between universities, researchers, government funding bodies and private investors.
B. Patent protection
Biotechnology inventions can require substantial investment in patent applications, scientific evidence and international protection.
C. Confidentiality
Unauthorised disclosure of laboratory methods and manufacturing information can undermine commercial value.
D. Biosafety compliance
The transfer of genetically modified materials requires attention to registration, risk assessment and applicable authorisations.
E. International licensing
Differences between Ukrainian and foreign intellectual property laws can complicate technology-transfer transactions.
F. Wartime restrictions
National security, export controls, research infrastructure disruption and special intellectual property provisions can affect technology-transfer operations.
G. Commercialisation difficulties
Research institutions may develop valuable inventions but lack sufficient resources for international patent protection and industrial-scale production.
18. Practical Compliance Framework for Biotechnology Companies
A biotechnology company transferring technology in Ukraine should follow a structured compliance process.
Technology transfer compliance process
Identify the technology
Identify patents, biological materials, research results, know-how and technical documentation.
Verify ownership
Examine employment contracts, research agreements, funding conditions and patent records.
Conduct legal due diligence
Check patent validity, ownership disputes, third-party rights and licensing restrictions.
Assess biosafety requirements
Determine whether GMO registration, risk assessment or regulatory authorisation is necessary.
Check export-control requirements
Classify biological materials, equipment and technical information before international transfer.
Execute the transfer agreement
Specify ownership, licence scope, royalties, confidentiality, liability and technical assistance.
Complete necessary formalities
Complete applicable intellectual property registrations and regulatory procedures.
Monitor compliance
Maintain records of transfers, payments, regulatory approvals and permitted uses.
19. Conclusion
Biotechnology Technology Transfer Law in Ukraine represents an important part of the country's intellectual property, scientific research, innovation and biosafety framework.
Law No. 143-V of 2006 provides the principal legal foundation for transferring technologies, assigning intellectual property rights, licensing innovations and commercialising publicly funded research.
The Civil Code and patent legislation provide additional contractual and intellectual property protections, while Law No. 3339-IX establishes the modern framework for genetic engineering activities and GMO regulation.
The Ukrainian Supreme Court decisions in Cases Nos. 366/599/19, 569/9366/17 and 757/49581/23-ц are particularly relevant to contractual classification, intellectual property transfers and registration requirements. Pharmaceutical patent decisions also provide useful guidance for biotechnology commercialisation.
Ultimately, a legally effective biotechnology technology-transfer arrangement requires more than a patent licence. It requires clear ownership, properly drafted contractual rights, confidentiality protection, appropriate biosafety compliance, regulatory authorisations and international export-control assessment.
The development of a transparent and reliable technology-transfer framework is therefore important for Ukraine's biotechnology industry, pharmaceutical manufacturing, agricultural innovation, international scientific partnerships and long-term technological development.
20. Important Legal References and Research Sources
Law No. 143-V of 2006 – Technology Transfer Law.
Law on the Protection of Rights to Inventions and Utility Models.
Civil Code of Ukraine – English text.
Law No. 3339-IX of 2023 – Genetic Engineering and GMO Regulation.
WIPO Lex – Ukrainian Technology Transfer Legislation.
Ukrainian Supreme Court – Intellectual Property Case Law.
Supreme Court decision, Case No. 910/9528/25.
Ukrainian Government – GMO Risk Assessment Commission, October 2026.
Research note: The legislation and case-law discussion reflects sources available as of 18 November 2026. The cited judgments should be distinguished from direct biotechnology technology-transfer cases: several establish general intellectual property or pharmaceutical patent principles rather than deciding a biotechnology transfer dispute itself.

comments